Mirum Pharmaceuticals (MIRM) News Today

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) shares climbed after the company reported stronger-than-expected Q2 results, raised full-year guidance and received multiple analyst price-target increases.

• Positive Sentiment: Q2 EPS loss of $0.12 beat the Zacks estimate by $0.19, while revenue of $127.8 million topped forecasts by $19.9 million, driven by 64% year-over-year growth. View Press Release
• Positive Sentiment: FY2025 revenue guidance was raised to $490–510 million versus the consensus $448.6 million, reflecting management’s confidence in ongoing momentum.
• Positive Sentiment: Zacks highlighted the Q2 earnings and revenue beat, noting an upgraded 2025 outlook following strong Livmarli sales. Zacks Article
• Positive Sentiment: JMP Securities raised its price target to $81 (Market Outperform), implying ~35% upside. Benzinga
• Positive Sentiment: Raymond James boosted its target to $82 and reiterated a Strong-Buy rating, suggesting ~37% upside. Benzinga
• Positive Sentiment: HC Wainwright lifted its target to $80 with a Buy rating, reflecting ~34% upside. Benzinga
• Neutral Sentiment: Full Q2 earnings call transcript and presentation are available for investors seeking management commentary. Transcript Presentation
• Neutral Sentiment: A detailed business update and financial summary are posted on Yahoo Finance for additional context. Yahoo Finance